Pluristem wins permit for muscle regeneration trial
Pluristem Therapeutics Ltd. (Nasdaq:PSTI; DAX: PJT: PLTR) has received permission from Germany’s Paul-Ehrlich-Institute (PEI), the country’s medical regulatory agency, to commence a Phase I/II clinical trial to assess the safety …
Congrats to @Pluristem! Hopefully the medical trials within Germany will convince other countries to permit Pluristem to use their medical technology to help save more lives.
